FDA Opioid Analgesics Risk Management Models Include Stadol NS, Actiq
Executive Summary
An FDA advisory committee will consider whether risk management models used for Bristol-Myers Squibb's Stadol NS, Sanofi-Synthelab's Talwin NX and Cephalon's Actiq should be more generally applied to other opioid analgesics.
You may also be interested in...
Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?
Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14
Bristol Discontinues Serzone, Stadol And 15 Other Brands; Safety In Numbers?
Bristol will cease distribution of the antidepressant Serzone (nefazodone) effective June 14
Opioid Analgesic Risk Management Should Not Inhibit Access, Cmte. Says
Risk management plans for opioid analgesics should be modified if it appears the plan inhibits access for the appropriate patient population, FDA's Anesthetic & Life Support Drugs Advisory Committee said